AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T06:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 ASX Stocks That May Be Trading At Discounts Up To 41.8%
Mon 01 Sep 25, 07:34 PMASX Value Stocks Trading Below Estimated Worth In August 2025
Sun 31 Aug 25, 07:34 PM| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -1.73000M | -31.10800M | 5.47M | 2.25M | 1.90M |
| Minority interest | - | - | - | - | - |
| Net income | -4.46000M | -25.32900M | 1.89M | 1.70M | 1.88M |
| Selling general administrative | 47.91M | 49.09M | 47.70M | 31.82M | 25.89M |
| Selling and marketing expenses | 0.87M | 0.88M | - | 0.69M | 0.12M |
| Gross profit | 63.47M | 59.75M | 67.09M | 42.63M | 28.48M |
| Reconciled depreciation | 6.35M | 6.21M | 5.36M | 1.63M | 1.04M |
| Ebit | 1.80M | -26.57200M | 9.43M | 2.91M | 2.08M |
| Ebitda | 8.14M | -20.35700M | 14.16M | 4.54M | 3.12M |
| Depreciation and amortization | 6.35M | 6.21M | - | 1.63M | 1.04M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 3.48M | 3.39M | 9.43M | 2.91M | 2.08M |
| Other operating expenses | 162.98M | 154.30M | 0.45M | 101.95M | 76.78M |
| Interest expense | 3.53M | 4.54M | 3.32M | 0.66M | 0.17M |
| Tax provision | 2.73M | -5.77900M | 3.59M | 0.55M | 0.02M |
| Interest income | 0.01000M | 0.08M | 0.01M | 0.00200M | 0.07M |
| Net interest income | -4.28600M | -4.66800M | -4.00200M | -1.26500M | -0.52200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.73M | -5.77900M | 3.59M | 0.55M | 0.02M |
| Total revenue | 166.46M | 155.02M | 162.15M | 107.57M | 76.57M |
| Total operating expenses | 59.99M | 62.33M | - | 37.01M | 28.70M |
| Cost of revenue | 102.99M | 95.27M | 95.06M | 64.94M | 48.08M |
| Total other income expense net | -5.21500M | -34.49500M | 0.05M | -2.10700M | 2.64M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -4.46000M | -25.32900M | 1.89M | 1.70M | 1.88M |
| Net income applicable to common shares | -4.46000M | -25.32900M | 1.89M | 1.70M | 1.88M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 195.63M | 188.00M | 229.04M | 206.78M | 99.38M |
| Intangible assets | 26.92M | 29.05M | 33.68M | 3.98M | 1.09M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.02M | 2.10M | 0.33M | 0.03M | 1.51M |
| Total liab | 90.01M | 85.15M | 99.51M | 90.27M | 33.30M |
| Total stockholder equity | 105.62M | 102.85M | 129.53M | 116.51M | 66.08M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 18.94M | 14.59M | 3.92M | 15.20M | 10.57M |
| Common stock | 101.75M | 101.47M | 101.25M | 96.26M | 48.17M |
| Capital stock | 101.75M | 101.47M | 101.25M | 96.26M | 48.17M |
| Retained earnings | -11.99700M | -7.53700M | 18.62M | 17.33M | 15.62M |
| Other liab | - | - | 10.77M | 0.32M | 0.60M |
| Good will | 59.86M | 57.15M | 80.57M | 103.43M | 1.09M |
| Other assets | - | - | 6.61M | 4.34M | 4.89M |
| Cash | 11.85M | 11.24M | 11.04M | 13.16M | 51.72M |
| Cash and equivalents | - | - | - | 0.89M | 0.75M |
| Total current liabilities | 34.23M | 72.15M | 39.20M | 80.15M | 24.11M |
| Current deferred revenue | - | 1.21M | - | - | - |
| Net debt | 43.64M | 44.92M | 37.59M | 53.02M | -34.69700M |
| Short term debt | 4.16M | 45.98M | - | 56.38M | 8.43M |
| Short long term debt | 1.66M | 44.10M | 9.93M | 54.84M | 7.29M |
| Short long term debt total | 55.49M | 56.16M | - | 66.18M | 17.02M |
| Other stockholder equity | - | - | 9.66M | 2.92M | 2.29M |
| Property plant equipment | - | - | 35.22M | 27.61M | 14.26M |
| Total current assets | 67.59M | 61.71M | 69.71M | 64.86M | 78.54M |
| Long term investments | 0.14M | 0.14M | 1.55M | 1.46M | 0.21M |
| Net tangible assets | - | - | 13.57M | 8.01M | 64.59M |
| Short term investments | - | - | - | - | 0.75M |
| Net receivables | 23.59M | 20.43M | 24.16M | 20.75M | 10.33M |
| Long term debt | 39.73M | - | 38.71M | 0.00000M | 0.00000M |
| Inventory | 29.13M | 27.93M | 31.93M | 28.27M | 13.57M |
| Accounts payable | 11.14M | 10.38M | 9.58M | 8.57M | 5.11M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 15.87M | 8.92M | - | 2.92M | 2.29M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 29.05M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 128.04M | 126.29M | 159.33M | 141.91M | 20.84M |
| Capital lease obligations | 14.10M | 12.06M | 12.67M | 11.34M | 9.73M |
| Long term debt total | - | - | - | 9.80M | 8.59M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -4.08700M | -3.04000M | -8.55300M | -1.31300M | 2.61M |
| Change to liabilities | - | - | 2.61M | 1.60M | 1.95M |
| Total cashflows from investing activities | -4.08700M | -3.04000M | -8.55300M | -116.38200M | 0.40M |
| Net borrowings | -3.38600M | -4.53100M | -7.89100M | 45.58M | -3.13800M |
| Total cash from financing activities | -5.64300M | -6.40000M | -3.36400M | 74.69M | 36.81M |
| Change to operating activities | - | - | 1.06M | 1.51M | 0.24M |
| Net income | -4.46000M | -25.32900M | 1.89M | 1.70M | 1.88M |
| Change in cash | 0.61M | 0.20M | -2.12600M | -38.55300M | 46.93M |
| Begin period cash flow | 11.24M | 11.04M | 13.16M | 51.72M | 4.79M |
| End period cash flow | 11.85M | 11.24M | 11.04M | 13.16M | 51.72M |
| Total cash from operating activities | 10.83M | 9.47M | 9.55M | 2.74M | 9.86M |
| Issuance of capital stock | - | - | 4.71M | 29.97M | 50.00M |
| Depreciation | - | 6.21M | 7.90M | 3.64M | 3.02M |
| Other cashflows from investing activities | - | - | - | -112.96700M | 1.51M |
| Dividends paid | - | - | - | -49.21500M | -3.35000M |
| Change to inventory | - | 4.01M | -3.59700M | -4.72000M | 1.18M |
| Change to account receivables | - | 3.11M | -3.17400M | -2.47100M | -3.53700M |
| Sale purchase of stock | - | 0.00000M | -0.18100M | -0.85700M | -7.11200M |
| Other cashflows from financing activities | -2.25700M | -1.86900M | -0.18100M | 47.27M | -1.18300M |
| Change to netincome | - | - | 1.61M | 2.41M | 4.13M |
| Capital expenditures | 4.09M | 3.04M | 8.55M | 3.42M | 1.11M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -148.44100M | 7.85M | - | -101.40900M | -61.58800M |
| Stock based compensation | - | 0.45M | - | - | - |
| Other non cash items | 10.83M | 20.74M | - | - | - |
| Free cash flow | 6.74M | 6.43M | 1.00M | -3.41500M | -1.10600M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TRJ Trajan Group Holdings Ltd |
-0.005 1.43% | 0.34 | - | 20.00 | 0.31 | 0.39 | 0.51 | 9.77 |
| RMD Resmed Inc |
0.66 2.55% | 26.50 | 19.97 | 17.76 | 7.59 | 4.70 | 5.30 | 13.47 |
| FPH Fisher & Paykel Healthcare Corporation Ltd |
0.13 0.43% | 30.40 | 51.75 | 42.37 | 7.90 | 11.31 | 15.26 | 29.64 |
| ANN Ansell Ltd |
-0.04 0.14% | 27.56 | 20.82 | 16.61 | 1.91 | 1.40 | 1.66 | 11.05 |
| NAN Nanosonics Ltd |
-0.06 1.90% | 3.10 | 45.57 | 46.30 | 4.60 | 4.41 | 3.93 | 25.73 |
Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India. The company offers analytical products, including syringes, GC columns and septa, inlet liners, rings, and tubing products; and sampling products, comprising septa, caps, liners, well plates and sealing mats, crimping tools, and micro sampling tools, as well as automation systems and consumables. It also provides pathology products, consisting of NBF containers, adhesive and frosted microscope slides, coverslips, microtome blades, biopsy pads, microscope slide storage trays/mailers, microscope slide and cassette storage boxes, histology wax plus, and tissue marking dyes and sets, and MiPlatform, a smartphone adapter; on-line and laboratory instruments and related parts and services; and miniaturized and portable instrumentation, as well as products and services related to microsampling. In addition, the company offers analytical, automation, life sciences, sampling literature support products. The company was incorporated in 2011 and is headquartered in Ringwood, Australia.
7 Argent Place, Ringwood, VIC, Australia, 3134
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen Tomisich | CEO, MD & Director | NA |
| Mr. Alister John Hodges CPA, CPA | CFO & Company Sec. | NA |
| Mr. Nigel Gilligan | Chief Operations Officer | NA |
| Dr. Andrew Arthur Gooley | Chief Scientific Officer | NA |
| Mr. Robert Lyon | Exec. Director, Head of Corp. Devel. & Gen. Counsel | NA |
| Mr. Sam Evans | Sr. VP of Bus. Devel. | NA |
| Ms. Helene Lajoie | Chief HR Officer | NA |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Joint Company Sec. | 1964 |
| Mr. Alister John Hodges CPA, CPA | CFO & Company Secretary | NA |
| Mr. Robert Lyon | Executive Director, Head of Corporate Development & General Counsel | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...